CRL Charles River Laboratories International, Inc. Common Stock
NYSE · Life Sciences Tools & Services · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 5, 2026
$290.19
· of 52w range
· above low
· to high
$146.2052w low
$303.3152w high
Market Cap (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
Revenue (TTM)
$4.00B
your badges
52W Range
$146–$303
Analyst Rating
BUY
Price Target
$305
P/E
-60.5
ROE
-7.7%
Net Profit Margin
-6.0%
Your badge strip is empty — pin a metric anywhere on this page.
CRL Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$290.19
Market Cap (MRQ)
$13.85B
P/E (TTM)
-60.5
EPS (TTM)
$-4.80
Revenue (TTM)
$4.00B
ROE (TTM)
-7.7%
Debt/Equity (MRQ)
0.0
52W Range
$146–$303
CRL Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Charles River Laboratories International, Inc. Common Stock Company overview from Wikipedia
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients.
Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryLife Sciences Tools & Services
employees18,300
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$4.02B2016-12-31 → 2025-12-27
EPS$-2.912016-12-31 → 2025-12-27
Free Cash Flow$518M2016-12-31 → 2025-12-27
Net margin-6.0%2016-12-31 → 2025-12-27
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | CRL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -60.55Y avg ≈191.6 | ≈191.6 | · | · | |
| P/S (TTM) | 3.55Y avg ≈3.2 | ≈3.2 | 4.9 | Undervalued | |
| P/B (MRQ) | 4.95Y avg ≈4.1 | ≈4.1 | 3.6 | Fair value | |
| EV / EBITDA | 32.85Y avg ≈16.9 | ≈16.9 | 25.4 | Undervalued | |
| Price / FCF (TTM) | 37.45Y avg ≈28.8 | ≈28.8 | · | · | |
| Price / Cash Flow (TTM) | 23.85Y avg ≈17.3 | ≈17.3 | 26.2 | Undervalued | |
| EV / Revenue | 3.55Y avg ≈3.1 | ≈3.1 | · | · | |
| EV / FCF | 27.15Y avg ≈28.3 | ≈28.3 | · | · | |
| Price / Tangible Book (MRQ) | 5.4 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | CRL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 2.3%5Y avg ≈10.8% | ≈10.8% | 12.1% | In line | |
| EBITDA Margin (TTM) | 9.7%5Y avg ≈19.2% | ≈19.2% | 14.8% | Top tier | |
| Pretax Margin | -2.5%5Y avg ≈8.6% | ≈8.6% | 12.4% | Weak | |
| Net Profit Margin (TTM) | -6.0%5Y avg ≈6.3% | ≈6.3% | 10.8% | Weak | |
| ROA (TTM) | -3.2%5Y avg ≈3.4% | ≈3.4% | 2.0% | Weak | |
| ROE (TTM) | -7.7%5Y avg ≈9.0% | ≈9.0% | 3.3% | Weak | |
| ROIC | 1.1%5Y avg ≈10.7% | ≈10.7% | 3.0% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | CRL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.05Y avg ≈0.0 | ≈0.0 | 0.1 | Low debt | |
| Current Ratio (MRQ) | 1.35Y avg ≈1.4 | ≈1.4 | 1.8 | Low liquidity | |
| Quick Ratio | 0.85Y avg ≈0.9 | ≈0.9 | 1.2 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | CRL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -0.85%5Y avg ≈6.9% | ≈6.9% | · | · | |
| Revenue CAGR 3Y | 0.33%5Y avg ≈5.7% | ≈5.7% | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | |
| EPS YoY | -97.8%5Y avg ≈-17.6% | ≈-17.6% | · | · | |
| Net Income YoY | -95.3%5Y avg ≈-16.5% | ≈-16.5% | · | · | |
| EPS CAGR 3Y | -70.3% | · | · | · | |
| Net Income CAGR 3Y | -61.6% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | CRL | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.55Y avg ≈0.5 | ≈0.5 | 0.5 | In line | |
| Receivables Turnover | 5.65Y avg ≈5.5 | ≈5.5 | 5.6 | In line | |
| Revenue / Employee | ≈$219.4K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
8.9%
Next Report
Nov 03, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 12, 2026 | $3.02 | $2.76 | 9.2% |
| March 31, 2026 | $2.06 | $1.96 | 5.0% | |
| Dec. 31, 2025 | $2.39 | $2.37 | 0.98% | |
| Sept. 30, 2025 | $2.43 | $2.36 | 2.9% | |
| June 30, 2025 | $3.12 | $2.52 | 23.7% | |
| March 31, 2025 | $2.34 | $2.10 | 11.4% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.30 | $67.69 | $70.06 | $58.42 | $50.21 | $42.49 | $33.40 | $27.33 | $22.05 | $17.67 | $15.70 | $14.20 | |
| Revenue / Share | $81.01 | $78.45 | $80.26 | $77.50 | $68.84 | $57.77 | $52.75 | $46.23 | $38.25 | $35.06 | · | · | |
| Cash Flow / Share | $14.88 | $14.23 | $13.29 | $12.08 | $14.79 | $10.80 | $9.68 | $9.00 | $6.55 | $6.26 | · | · | |
| Cash / Share | $4.34 | $3.81 | $5.39 | $4.59 | $4.78 | $4.59 | $4.86 | $4.05 | $3.46 | $2.48 | $2.53 | $3.38 | |
| EPS (TTM) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | · | 49,213,000 | 49,149,000 | 50,677,000 | · | 51,394,000 | 51,551,000 | 51,437,000 | · | 51,283,000 | 51,097,000 | · | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | · | 49,426,000 | 49,316,000 | 50,853,000 | · | 51,583,000 | 51,846,000 | 51,842,000 | · | 51,607,000 | 51,428,000 | · | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $59.50 | $61.05 | · | $69.20 | $68.14 | $65.04 | · | $73.97 | $72.13 | $70.67 | · | $64.45 | · | · | $51.63 | |
| Revenue / Share | $20.91 | $20.34 | · | $20.33 | $20.93 | $19.35 | · | $19.58 | $19.79 | $19.51 | · | $19.89 | $20.02 | · | $19.29 | |
| Cash Flow / Share | · | $0.84 | · | · | · | $3.38 | · | · | · | $2.51 | · | · | $2.13 | · | · | |
| Cash / Share | $4.02 | $3.98 | · | $4.21 | $3.72 | $4.67 | · | $4.11 | $3.47 | $6.35 | · | $3.06 | · | · | $3.81 | |
| EPS (TTM) | $-4.80 | $-3.71 | · | $-1.51 | $-1.28 | $-0.60 | · | $8.01 | $8.37 | $8.52 | · | $9.25 | $9.68 | · | $8.49 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.00B | $4.03B | · | $4.02B | $4.03B | $4.02B | · | $4.06B | $4.08B | $4.11B | · | $4.22B | $4.09B | · | $3.78B | |
| Net Income TTM | $-238M | $-185M | · | $-82M | $-67M | $-25M | · | $424M | $442M | $444M | · | $475M | $496M | · | $436M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | -44.9 | -42.9 | · | -98.4 | -117.2 | -259.2 | · | 24.8 | 24.7 | 31.8 | · | 21.2 | 20.8 | · | 22.1 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | 2.5 | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.6 | 3.3 | · | 2.3 | 2.5 | · | 2.5 | |
| Earnings Yield | -2.2% | -2.3% | · | -1.0% | -0.85% | -0.39% | · | 4.0% | 4.0% | 3.1% | · | 4.7% | 4.8% | · | 4.5% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Operating Margin % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Net Income | $-144M | $22M | $475M | $486M | $391M |
| Diluted EPS | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Metric | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
| Metric | 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 |
|---|---|---|---|---|---|
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M |
Institutional owners (13F) 607 filers · $13.6B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
607
Value held
$13.6B
New positions
74
Exited positions
62
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 74 (-17 vs prior Q) | 62 (-19 vs prior Q) | 193 (0 vs prior Q) | 204 (+13 vs prior Q) | +2.8M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1,174,373,670 | 5,887,175 | 8.65% | Shares |
| FMR LLC | $961,533,236 | 4,239,752 | 7.09% | Shares |
| BlackRock, Inc. | $861,475,349 | 3,798,560 | 6.35% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $714,227,026 | 3,149,288 | 5.26% | Shares |
| Invesco Ltd. | $676,919,391 | 2,984,785 | 4.99% | Shares |
| HARRIS ASSOCIATES L P | $508,269,048 | 2,241,144 | 3.75% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501,427,927 | 2,210,979 | 3.70% | Shares |
| Allspring Global Investments Holdings, LLC | $436,473,035 | 1,905,247 | 3.22% | Shares |
| STATE STREET CORP | $422,800,968 | 1,864,284 | 3.12% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $373,848,597 | 1,648,450 | 2.76% | Shares |
| ARIEL INVESTMENTS, LLC | $341,587,697 | 1,506,185 | 2.52% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $295,598,099 | 1,305,738 | 2.18% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $292,210,525 | 1,288,463 | 2.15% | Shares |
| CITADEL ADVISORS LLC | $270,696,771 | 1,193,601 | 1.99% | Shares |
| BANK OF AMERICA CORP /DE/ | $265,930,779 | 1,172,586 | 1.96% | Shares |
| EARNEST PARTNERS LLC | $254,007,295 | 1,120,011 | 1.87% | Shares |
| AMERIPRISE FINANCIAL INC | $199,834,979 | 881,189 | 1.47% | Shares |
| NEUBERGER BERMAN GROUP LLC | $195,633,630 | 862,704 | 1.44% | Shares |
| SEI INVESTMENTS CO | $184,499,540 | 813,530 | 1.36% | Shares |
| MORGAN STANLEY | $181,542,851 | 800,487 | 1.34% | Shares |
| Clearbridge Investments, LLC | $177,185,527 | 781,276 | 1.31% | Shares |
| COOKE & BIELER LP | $171,369,328 | 755,630 | 1.26% | Shares |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $157,642,604 | 682,173 | 1.16% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $150,762,735 | 664,768 | 1.11% | Shares |
| UBS Group AG | $146,675,752 | 646,747 | 1.08% | Shares |
| GOLDMAN SACHS GROUP INC | $145,100,822 | 639,803 | 1.07% | Shares |
| MILLENNIUM MANAGEMENT LLC | $110,324,717 | 486,462 | 0.81% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $106,061,291 | 467,663 | 0.78% | Shares |
| BANK OF MONTREAL /CAN/ | $104,270,783 | 459,768 | 0.77% | Shares |
| NORTHERN TRUST CORP | $101,169,205 | 446,092 | 0.75% | Shares |
| Gotham Asset Management, LLC | $98,233,181 | 433,146 | 0.72% | Shares |
| Amundi | $93,528,650 | 412,402 | 0.69% | Shares |
| NORGES BANK | $83,921,372 | 370,040 | 0.62% | Shares |
| MARSHALL WACE, LLP | $77,787,835 | 342,995 | 0.57% | Shares |
| Iron Triangle Partners LP | $75,748,141 | 379,728 | 0.56% | Shares |
| CITIGROUP INC | $71,714,853 | 316,217 | 0.53% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $69,108,583 | 304,725 | 0.51% | Shares |
| Bank of New York Mellon Corp | $69,054,385 | 304,486 | 0.51% | Shares |
| Boston Trust Walden Corp | $65,523,486 | 288,917 | 0.48% | Shares |
| JPMORGAN CHASE & CO | $65,085,033 | 286,317 | 0.48% | Shares |
| ALLIANCEBERNSTEIN L.P. | $64,615,913 | 374,585 | 0.48% | Shares |
| SNYDER CAPITAL MANAGEMENT L P | $63,899,443 | 281,756 | 0.47% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63,174,169 | 278,558 | 0.47% | Shares |
| DEUTSCHE BANK AG\ | $62,723,084 | 276,569 | 0.46% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $61,384,115 | 270,665 | 0.45% | Shares |
| PRIMECAP MANAGEMENT CO/CA/ | $60,523,448 | 266,870 | 0.45% | Shares |
| RAYMOND JAMES FINANCIAL INC | $58,234,910 | 256,779 | 0.43% | Shares |
| Meridiem Capital Partners LP | $56,012,367 | 246,979 | 0.41% | Shares |
| Alyeska Investment Group, L.P. | $53,295,650 | 235,000 | 0.39% | Shares |
| LOOMIS SAYLES & CO L P | $50,725,593 | 223,668 | 0.37% | Shares |
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 filings | Aug. 4, 2011 | · | Initial filing | · | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 filings | Feb. 9, 2011 | · | Initial filing | · | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 filings | Dec. 7, 2010 | · | Initial filing | · | SEC |
| Undisclosed reporting person | June 16, 2010 | · | Initial filing | · | SEC |
| Undisclosed reporting person | June 7, 2010 | · | Initial filing | Passive investment | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | May 5, 2010 | · | Initial filing | Board campaign | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 57 insiders · 23 officers · 29 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Birgit Girshick | Chief Executive Officer | Aug. 19, 2026 G | 35,485 | 0 | 1 | $-1,819,350 |
| Glenn Coleman | EVP & Chief Financial Officer | Sept. 30, 2026 P | 27,762 | 1 | 0 | $2,974 |
| Flavia Pease | Corporate Executive VP & CFO | May 31, 2025 F | 17,297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | March 3, 2022 M | 25,819 | 0 | 0 | $0 |
| Davide Molho | President & COO | July 24, 2018 M | 17,155 | 0 | 0 | $0 |
| Shannon M Parisotto | CEVP, Disc & Safety Assessment | Aug. 19, 2026 M | 4,807 | 0 | 3 | $-2,965,466 |
| Mark Mintz | EVP, Chief Information Officer | May 31, 2026 F | 9,546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | Nov. 7, 2024 G | 23,337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | June 1, 2020 A | 3,171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | May 29, 2020 A | 224,478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | Oct. 1, 2016 F | 5,599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | March 2, 2016 S | 11,034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | Feb. 25, 2015 M | 14,094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | Aug. 11, 2010 F | 74,390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | Feb. 26, 2010 A | 31,897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | Aug. 11, 2007 F | 37,109 | 0 | 0 | $0 |
| David J Elliott | Officer | June 29, 2007 M | 11,750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | May 1, 2007 A | 6,262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | April 2, 2007 A | 11,500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | April 2, 2007 F | 12,713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | Feb. 23, 2007 A | 12,710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | Feb. 27, 2006 S | 16,134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | Dec. 23, 2004 M | 8,000 | 0 | 0 | $0 |
| James C Foster | Director | Aug. 25, 2026 M | 31,596 | 0 | 3 | $-34,844,875 |
| Nancy C Andrews | Director | Aug. 18, 2026 M | 1,438 | 0 | 1 | $-163,443 |
| Steven Barg | Director | June 2, 2026 A | 3,287 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Director | May 8, 2026 A | 4,563 | 0 | 0 | $0 |
| George Llado | Director | May 8, 2026 A | 6,702 | 0 | 0 | $0 |
| Abraham Ceesay | Director | May 8, 2026 A | 2,384 | 0 | 0 | $0 |
| Mark J Enyedy | Director | May 8, 2026 A | 2,384 | 0 | 0 | $0 |
| Paul W Graves | Director | May 8, 2026 A | 2,384 | 0 | 0 | $0 |
| Craig B. Thompson | Director | May 8, 2026 A | 3,851 | 0 | 0 | $0 |
| Martin Mackay | Director | May 8, 2026 A | 17,137 | 0 | 0 | $0 |
| Virginia M Wilson | Director | May 8, 2026 A | 6,349 | 0 | 0 | $0 |
| George Massaro | Director | May 15, 2025 S | 5,575 | 0 | 0 | $0 |
| Richard F Wallman | Director | Nov. 7, 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Director | May 13, 2024 A | 7,894 | 0 | 0 | $0 |
| Robert J Bertolini | Director | May 13, 2024 A | 32,802 | 0 | 0 | $0 |
| Richard C Reese | Director | May 15, 2023 A | 65,541 | 0 | 0 | $0 |
| George M Milne JR | Director | May 7, 2021 A | 29,079 | 0 | 0 | $0 |
| Stephen D Chubb | Director | Feb. 23, 2021 M | 40,529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Director | May 22, 2019 A | 3,886 | 0 | 0 | $0 |
| William Waltrip | Director | Dec. 5, 2012 S | 21,830 | 0 | 0 | $0 |
| Samuel O Thier MD | Director | May 9, 2012 A | 18,230 | 0 | 0 | $0 |
| Douglas E Rogers | Director | May 7, 2010 A | 12,859 | 0 | 0 | $0 |
| Nancy T Chang | Director | May 7, 2010 A | 31,010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Director | Feb. 13, 2006 A | · | 0 | 0 | $0 |
| Walter S Nimmo | Director | Feb. 25, 2005 S | 149,447 | 0 | 0 | $0 |
| John Urquhart | Director | Feb. 17, 2005 A | 11,738 | 0 | 0 | $0 |
| Louise S Mccrary | Director | Feb. 17, 2005 A | · | 0 | 0 | $0 |
| Robert Cawthorn | Director | June 2, 2004 G | 278,600 | 0 | 0 | $0 |
| Joseph W Laplume | · | Aug. 10, 2026 G | 31,041 | 1 | 1 | $-61,124 |
| Victoria L Creamer | · | Aug. 6, 2026 M | 30,051 | 0 | 1 | $-1,083,030 |
| Michael Gunnar Knell | · | Aug. 6, 2026 M | 11,852 | 0 | 9 | $-1,730,250 |
| Thomas F Ackerman | · | Feb. 29, 2016 F | 111,346 | 0 | 0 | $0 |
| Dennis R Shaughnessy | · | Nov. 29, 2004 G | 35,511 | 0 | 0 | $0 |
| Michael F Ankcorn | · | Nov. 4, 2004 S | 0 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 108 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| EPSB · Harbor ETF Trust | 2.15% | 443 NS | July 31, 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 2.00% | 20,123 SH | Oct. 2, 2026 | Daily |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.71% | 5,092 NS | July 31, 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.70% | 51,688 SH | Oct. 2, 2026 | Daily |
| EPSV · Harbor ETF Trust | 1.59% | 415 NS | July 31, 2026 | N-PORT |
| EPMV · Harbor ETF Trust | 1.44% | 291 NS | July 31, 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 1.09% | 4,303 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.96% | 363,741 SH | Sept. 11, 2026 | Daily |
| LSEQ · Harbor ETF Trust | 0.93% | 614 NS | July 31, 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0.74% | 2,375 NS | July 31, 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.66% | 259 NS | July 31, 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 0.66% | 22,191 SH | Oct. 2, 2026 | Daily |
| PDP · Invesco Exchange-Traded Fund Trust | 0.66% | 33,984 SH | Oct. 2, 2026 | Daily |
| PALC · Pacer Funds Trust | 0.61% | 5,509 NS | July 31, 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.49% | 12,141 NS | July 31, 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.45% | 6,439 NS | July 31, 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0.42% | 24,876 SH | Oct. 2, 2026 | Daily |
| FFSM · FIDELITY COVINGTON TRUST | 0.40% | 25,814 NS | July 31, 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.34% | 209,615 NS | July 31, 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.28% | 7,783 NS | July 31, 2026 | N-PORT |
| ESML · iShares Trust | 0.24% | 25,082 SH | Sept. 11, 2026 | Daily |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.24% | 20,898 NS | July 31, 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0.24% | 25,378 NS | July 31, 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.23% | 13,626 NS | July 31, 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0.23% | 701,498 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.22% | 147,648 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 0.22% | 28,670 SH | Sept. 11, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.21% | 701,283 SH | Oct. 2, 2026 | Daily |
| SMMD · iShares Trust | 0.19% | 26,152 SH | Sept. 11, 2026 | Daily |
| IXJ · iShares Trust | 0.17% | 25,598 SH | Sept. 11, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.17% | 23,486 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.16% | 148,331 SH | Aug. 19, 2026 | Daily |
| REVS · Columbia ETF Trust I | 0.15% | 2,111 NS | July 31, 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.15% | 3,646 NS | July 31, 2026 | N-PORT |
| WSML · iShares Trust | 0.14% | 6,080 SH | Sept. 11, 2026 | Daily |
| IWS · iShares Trust | 0.13% | 73,404 SH | Sept. 11, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.13% | 1,102,914 SH | Aug. 19, 2026 | Daily |
| CURE · Direxion Shares ETF Trust | 0.13% | 947 NS | July 31, 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.12% | 42,976 NS | July 31, 2026 | N-PORT |
| IEUS · iShares Trust | 0.10% | 5,579 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.10% | 2,769 SH | Oct. 2, 2026 | Daily |
| IWR · iShares Trust | 0.10% | 200,615 SH | Sept. 11, 2026 | Daily |
| RECS · Columbia ETF Trust I | 0.10% | 23,999 NS | July 31, 2026 | N-PORT |
| XOEF · iShares Trust | 0.07% | 61 SH | Sept. 11, 2026 | Daily |
| DFUV · Dimensional ETF Trust | 0.06% | 41,352 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.06% | 1,302 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.05% | 106,991 NS | July 31, 2026 | N-PORT |
| IVE · iShares Trust | 0.04% | 79,930 SH | Sept. 11, 2026 | Daily |
| IUSV · iShares Trust | 0.04% | 42,675 SH | Sept. 11, 2026 | Daily |
| SCZ · iShares Trust | 0.04% | 171,786 SH | Sept. 11, 2026 | Daily |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 174,824 SH | Aug. 19, 2026 | Daily |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.04% | 11,139 SH | Aug. 19, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.04% | 5,545 NS | July 31, 2026 | N-PORT |
| IWD · iShares Trust | 0.04% | 108,791 SH | Sept. 11, 2026 | Daily |
| CHRI · Global X Funds | 0.03% | 11 NS | July 31, 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 29,579 SH | Aug. 19, 2026 | Daily |
| TOPC · iShares Trust | 0.03% | 32 SH | Sept. 11, 2026 | Daily |
| PRF · Invesco Exchange-Traded Fund Trust | 0.03% | 9,073 SH | Oct. 2, 2026 | Daily |
| DFSU · Dimensional ETF Trust | 0.02% | 2,431 NS | July 31, 2026 | N-PORT |
| XVV · iShares Trust | 0.02% | 576 SH | Sept. 11, 2026 | Daily |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.02% | 1,258 SH | Oct. 2, 2026 | Daily |
| PBP · Invesco Exchange-Traded Fund Trust | 0.02% | 287 SH | Oct. 2, 2026 | Daily |
| EGLE · Global X Funds | 0.02% | 2 NS | July 31, 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.02% | 7,022 SH | Oct. 2, 2026 | Daily |
| IVV · iShares Trust | 0.02% | 607,129 SH | Sept. 11, 2026 | Daily |
| VOO · VANGUARD INDEX FUNDS | 0.02% | 1,250,774 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 1,530,468 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 8,168 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 4,112 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.02% | 11,106 SH | Aug. 19, 2026 | Daily |
| IWV · iShares Trust | 0.02% | 14,165 SH | Sept. 11, 2026 | Daily |
| IWB · iShares Trust | 0.02% | 33,863 SH | Sept. 11, 2026 | Daily |
| XRMI · Global X Funds | 0.02% | 41 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.02% | 9,979 NS | July 31, 2026 | N-PORT |
| XYLD · Global X Funds | 0.02% | 2,566 NS | July 31, 2026 | N-PORT |
| IYY · iShares Trust | 0.02% | 2,018 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.02% | 63,582 SH | Sept. 11, 2026 | Daily |
| PTLC · Pacer Funds Trust | 0.02% | 2,492 NS | July 31, 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0.02% | 38 SH | Oct. 2, 2026 | Daily |
| TILT · FlexShares Trust | 0.02% | 1,620 NS | July 31, 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.02% | 14,645 NS | July 31, 2026 | N-PORT |
| XYLG · Global X Funds | 0.02% | 45 NS | July 31, 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.02% | 182 NS | July 31, 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0.02% | 1,141 NS | July 31, 2026 | N-PORT |
| XTR · Global X Funds | 0.01% | 3 NS | July 31, 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.01% | 332 NS | July 31, 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.01% | 3,766 NS | July 31, 2026 | N-PORT |
| IEUR · iShares Trust | 0.01% | 37,473 SH | Sept. 11, 2026 | Daily |
| XCLR · Global X Funds | 0.01% | 2 NS | July 31, 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.01% | 1,973 SH | Oct. 2, 2026 | Daily |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 110,946 SH | Aug. 19, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 77,796 SH | Aug. 19, 2026 | Daily |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.01% | 447,656 SH | Aug. 19, 2026 | Daily |
| IDEV · iShares Trust | 0.01% | 52,174 SH | Sept. 11, 2026 | Daily |
| IEFA · iShares Trust | 0.00% | 272,340 SH | Sept. 11, 2026 | Daily |
| NEAR · iShares U.S. ETF Trust | 0.00% | 140,000 SH | Sept. 9, 2026 | Daily |
| DFLV · Dimensional ETF Trust | 0.00% | 377 NS | July 31, 2026 | N-PORT |
| IXUS · iShares Trust | 0.00% | 22,623 SH | Sept. 11, 2026 | Daily |
| VXUS · VANGUARD STAR FUNDS | 0.00% | 664,961 SH | Aug. 19, 2026 | Daily |
| VSGX · VANGUARD WORLD FUND | 0.00% | 8,805 SH | Aug. 19, 2026 | Daily |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | · | · | July 15, 2026 | Daily |
| VCRB · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VPLS · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VSDB · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VGMS · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| ISCB · iShares Trust | · | 2,146 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 10,576 SH | Sept. 11, 2026 | Daily |
| SMLF · iShares Trust | · | 18,703 SH | Sept. 11, 2026 | Daily |
CRL Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 23 analysts
BUY
Median target
$322.00
+11.0%
6 26.1%
Strong Buy
11 47.8%
Buy
6 26.1%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
15 analysts · 2026-10-02Mean target $305.00 +5.1%
Now
Current price $290.19
Low$145.00
Mean$305.00
High$357.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
| TECH | $11.03B | 60.9 | -0.38% | 15.0% | 9.0% | 65.8% |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | · |
| AVTR | $7.82B | -14.7 | -3.4% | -8.1% | -8.9% | 32.6% |
| BIO | · | · | · | · | · | · |
Latest News Recent headlines mentioning this company
Bio-Techne Takes Over #477 Spot From Charles River Laboratories International
Nasdaq · 3 months ago
Charles River Laboratories International Q1 Earnings Call Highlights
Yahoo Finance · 4 months, 3 weeks ago
Tokenized Crypto US Treasuries Near $14 Billion as Circle and BlackRock Lead Growth
Yahoo Finance · 5 months, 2 weeks ago
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 5, 2026